Key result
A 2024 review highlighted ten key papers on thrombosis and antithrombotic therapy that confirm current practice, induce moderation, or focus on new developments.
Provides a curated summary of the top 10 most impactful papers in thrombosis and antithrombotic treatment from 2024.
Answers are grounded in this paper and cite their sources.
Provides clinicians a concise thrombosis update; confirms current practice while highlighting moderation and new developments.
Ten 2024 papers on thrombosis and antithrombotic therapy with potential impact on clinical practice. Some confirm current practice, others induce moderation or focus on new developments. ACS, acute coronary syndrome; AF, atrial fibrillation; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; F, factor; HBR, high bleeding risk; IPDM, individual patient–data meta-analysis; OAC, oral anticoagulant; PE, pulmonary embolism; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation; VKA, Vitamin K antagonist.
No takes yet. Share an insight, caveat, or question.
Andreotti et al. (2025) conducted a review in Thrombosis and antithrombotic therapy. A 2024 review highlighted ten key papers on thrombosis and antithrombotic therapy that confirm current practice, induce moderation, or focus on new developments.
Synapse has enriched 10 related papers. Consider them for comparative context: